| Revenue growth | Standalone up 14% YoY; Consolidated down 8% YoY. |
|---|---|
| Margins | Standalone Gross Margins improved to 78% from 69%. |
| Demand visibility | Strong poultry demand; Animal health impacted by tender timing. |
| Management confidence | Confident in long-term growth despite short-term tender delays. |
Growth
Standalone revenue grew 14% YoY; Poultry Healthcare rose 48% due to higher institutional sales. Consolidated revenue fell 8% on Africa/Nepal weakness.
Outlook
Management focuses on expanding market penetration and strengthening biologicals portfolio across Poultry and Animal Healthcare divisions.
Risks
Animal Healthcare segment down 50% due to government tender delays. Profitability heavily dependent on one-time accounting gains.
Last quarter's promises, checked
Delivered
- Guided focus on bottom line → delivered Standalone PAT up 174% (= BEAT)
- Guided stronger execution in Poultry → delivered 41% Q4 segment growth (= BEAT)
- Targeted debt reduction → delivered debt reduced from INR 102cr to INR 70cr (= BEAT)
Partly delivered
- Targeted BSL-3 facility ramp-up → delivered ongoing optimization initiatives (= PARTIAL)
Missed
- Guided Animal Health recovery → delivered segment revenue down 50% (= MISS)
Earnings Call Transcript filed with NSE, NSE: HESTERBIO. Summary written with AI assistance from the document.
Hester Biosciences Ltd: key numbers
- Share price
- ₹2,182.90
- Market cap
- ₹1,857 Cr
- Revenue (annual)
- ₹332.6 Cr
- Net profit (annual)
- ₹55.64 Cr
- P/E (TTM)
- 13.6×Sector 50.4×
- Promoter holding
- 53.73%+0.00% QoQ
- FII holding
- 0.31%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hester Biosciences Ltd
All →Hester Biosciences Promoter Reclassification
Hester Biosciences Limited received shareholder approval to reclassify Mr. Ravin Gandhi and Ms. Bela Gandhi from the 'Promoter' category to the 'Public' category.
Hester Biosciences Annual General Meeting
Hester Biosciences Limited shareholders approved the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public' category via postal ballot.
Hester Biosciences Q1 FY27 Results: Net Profit ₹96.7 Cr, Up 459.0% YoY
Hester Biosciences Ltd reported revenue from operations of ₹77.2 Cr (-8.2% YoY) and net profit of ₹96.7 Cr (+459.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹96.7 Cr · +459.0% YoY
Hester Biosciences Earnings Call: Key Takeaways
Hester Biosciences reported Q4 and FY26 results with consolidated revenue growth of 22% and substantial PAT increase. Strategy focuses on biologicals, capacity utilization, and African market expansion.
Hester Biosciences Earnings Call: Key Takeaways
Hester Biosciences reported FY26 consolidated revenue of ₹3,325.99 Mn (₹332.60 Cr) and PAT of ₹57.48 Cr, focusing on global expansion in animal and poultry vaccines.
Hester Biosciences Earnings Call: Key Takeaways
Hester Biosciences delivered a strong Q3 FY26 with standalone revenue up 12% and PAT up 140%, driven by robust Poultry Healthcare performance and operational leverage despite Animal Healthcare headwinds.